Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas

Neuroendocrinology - Tập 89 Số 2 - Trang 223-230 - 2009
Vito D. Corleto1, Massimo Falconi2, Francesco Panzuto3, Massimo Milione3, Ottavia De Luca3, Pasquale Perri4, Renato Cannizzaro5, Cesare Bordi6, Paolo Pederzoli2, Aldo Scarpa2, Gianfranco Delle Fave7
1Sant'Andrea Hospital
2Univ of Verona
3University of Rome, La Sapienza
4Istituto Nazionale Tumori “Regina Elena”
5Oncology Referral Centre
6University of Parma#TAB#
7Medical-surgical Sciences and Translational Medicine

Tóm tắt

The majority of gastroenteropancreatic well-differentiated endocrine carcinomas (WDEC) express somatostatin receptors (SSTR). To correlate the expression of SSTR subtypes by reverse transcriptase-polymerase chain reaction (RT-PCR) with clinicopathological features and survival in a group of WDEC patients, 42 WDEC tissue specimens from 33 patients were analysed. All patients were treated with somatostatin analogues and had a median follow-up period of 45 months (range 6–196). Neither SSTR2 and SSTR5 expression nor Ki-67 level alone correlated with survival. A significantly better survival rate was observed in patients with tumours expressing SSTR2, SSTR5 and Ki-67 <2%, compared to those with SSTR2– and SSTR5–negative tumours and Ki-67 ≥2% (p < 0.038), with 5-year survival rates of 91 vs. 43%, respectively. Expression of SSTR2 and SSTR5 appears to play a positive prognostic role, possibly correlated with the high affinity that the available somatostatin analogues display for these 2 specific SSTR subtypes.

Từ khóa


Tài liệu tham khảo

10.1016/0022-2496(78)90059-7

10.1111/j.1440-1819.2005.01403.x

10.1016%2Fj.dld.2003.11.013

10.1016/j.bandc.2009.06.007

10.1046%2Fj.1365-2036.2000.00738.x

10.1080/10888430701530417

10.1046/j.0021-9630.2003.00305.x

10.1098/rstb.2012.0403

10.1111/jcpp.12001

10.1097/00004583-200008000-00025

10.1080/09297049.2012.727792

10.1179/146701011X13001035752570

10.1007/s11881-009-0022-0

10.1097/00005053-200203000-00003

10.1080/17470210500162854

10.1080/13682820802425693

10.1055/s-2004-833672

10.1530%2Feje.0.1510107

10.1037/0022-0663.98.2.247

10.1076/chin.8.4.249.13513

10.1016%2FS1010-7940%2802%2900055-6

10.1016%2Fj.jhep.2004.03.018

10.1080/02643290600787721

10.1111/j.1469-7610.2012.02557.x

10.3171%2Fjns.2003.99.4.0674

Thông tin
Thông tin xuất bản

Neuroendocrinology

Tập 89 Số 2

223-230

Thông tin tác giả